AC and Weekly Paclitaxel Improve Outcomes in TNBC

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Improvement in DFS With Weekly Paclitaxel in Patients With TNBC

    DFS, disease-free survival; D1, weekly docetaxel; D3, every-3-weeks docetaxel; P1, weekly paclitaxel; P3, every-3-weeks paclitaxel; TNBC, triple-negative breast cancer.

    a10-y rate, % (95% CI).

    Reproduced with permission from JA Sparano, MD.

Back to top

Tools

View Full Page PDF
Citation Tools
Email
AC and Weekly Paclitaxel Improve Outcomes in TNBC
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

adjuvant therapy
combination treatment
axillary node positive
disease-free survival
doxorubicin
cyclophosphamide
paclitaxel
A Phase 3 Study of Doxorubicin-Cyclophosphamide Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer
E1199
BC
NCT00004125